4 unchanged sentences
Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
−Removed: Notwithstanding the foregoing, there can be no assurance that the Company's disclosures controls and procedures will detect or uncover all failures of persons within the Company and its consolidated subsidiaries to disclose material information otherwise required to be set forth in the Company's periodic reports.
+Added: Notwithstanding the foregoing, there can be no assurance that the Company's disclosure controls and procedures will detect or uncover all failures of persons within the Company and its consolidated subsidiaries to disclose material information otherwise required to be set forth in the Company's periodic reports.
There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.
12 unchanged sentences
Based on this assessment, management concluded that, as of December 31, 2025, the Company’s internal control over financial reporting was effective.
+Added: Under guidelines established by the SEC, companies may exclude an acquired business from their assessment of internal control over financial reporting during the first year following an acquisition while integration activities are ongoing.
+Added: Accordingly, management’s assessment excluded internal control over financial reporting for Lehan, which is included in the 2025 consolidated financial statements of the Company and constituted 2.9% of total assets as of December 31, 2025 and 5.3% of revenues for the year then ended.
+Added: The Company is in the process of integrating Lehan’s internal control environment into its overall internal control framework.
The effectiveness of the Company's internal control over financial reporting as of December 31, 2025 has been audited by Ernst & Young LLP, an independent registered public accounting firm, as stated in their attestation report included in this Annual Report on Form 10-K, which expresses an unqualified opinion on the effectiveness of the Company's internal control over financial reporting as of December 31, 2025.
5 unchanged sentences
(the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on the COSO criteria.
−Removed: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of income and comprehensive income, changes in shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated March 10, 2025 expressed an unqualified opinion thereon.
+Added: As indicated in the accompanying Management Report on Internal Control over Financial Reporting, management’s assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of Lehan Drugs, Inc., which is included in the 2025 consolidated financial statements of the Company and constituted 2.9% of total assets as of December 31, 2025 and 5.3% of revenues for the year then ended.
+Added: Our audit of internal control over financial reporting of the Company also did not include an evaluation of the internal control over financial reporting of Lehan Drugs, Inc.
+Added: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of income changes in shareholders’ equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes and our report dated March 4, 2026 expressed an unqualified opinion thereon.
Basis for Opinion
25 unchanged sentences
This code is available on the corporate governance section of our website (which is a subsection of the investor relations section of our website) at the following address:
−Removed: www.viemed.com/investor-relations.
+Added: www.viemed.com/investors.
We intend to disclose on our website any amendments or waivers to the code that are required to be disclosed by SEC rules.
14 unchanged sentences
• Consolidated Balance Sheets as of December 31, 2025 and 2024
−Removed: • Consolidated Statements of Income and Comprehensive Income for the years ended December 31, 2024, 2023, and 2022
+Added: • Consolidated Statements of Income for the years ended December 31, 2025, 2024, and 2023
• Consolidated Statements of Changes in Shareholders’ Equity for the years ended December 31, 2025, 2024, and 2023
43 unchanged sentences
Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 11, 2020.
−Removed: +10.13 Form of Restricted Stock Units Agreement.
−Removed: Incorporated by reference to Exhibit 10.23 to the Company’s Annual Report on Form 10-K filed on March 3, 2021.
−Removed: +10.14 Form of Award Agreement for Stock Option.
−Removed: Incorporated by reference to Exhibit 10.24 to the Company’s Annual Report on Form 10-K filed on March 3, 2021.
−Removed: +10.15 Form of Restricted Stock Unit Award.
−Removed: Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on November 2, 2021.
−Removed: +10.16 Non-Employee Directors Deferred Compensation Plan.
−Removed: Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on November 2, 2021.
10.13 First Amendment to Credit Agreement dated November 29, 2022, among Viemed Inc.
4 unchanged sentences
Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 6, 2024.
−Removed: Vi emed He althcare, Inc .
−Removed: Insider Trading Pol icy, dated January 21, 2025.
+Added: 10.15 Second Amendment to Credit Agreement dated November 29, 2022, among Viemed Inc.
+Added: as borrower, certain subsidiaries of Viemed, Inc., as guarantors, the lenders from time to time party thereto, and Regions Bank, as administrative agent and collateral agent, effective June 6, 2025.
+Added: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 9, 2025.
+Added: 10.16 Third Amendment to Credit Agreement dated November 29, 2022, among Viemed Inc.
+Added: as borrower, certain subsidiaries of Viemed, Inc., as guarantors, the lenders from time to time party thereto, and Regions Bank, as administrative agent and collateral agent, effective November 7 , 2025.
+Added: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 7 , 2025.
+Added: Amendment to the 2024 Long Term Incentive Plan, effective June 5, 2025.
+Added: Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 5, 2025.
+Added: Form of Restricted Stock Units Agreement (Employee s ) .
+Added: Form of Restricted Stock Units Agreement ( Non-Employee Direc tor s ) .
+Added: Executive Employment Agreement dated effective June 3, 2019 by and between Trae Fitzgerald and Sleep Management, LLC.
+Added: Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on May 7, 2025.
+Added: Executive Employment Agreement dated effective August 1, 2022 by and between Jeremy Trahan and Sleep Management, LLC.
+Added: Incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on May 7, 2025.
+Added: 19.1 Viemed Healthcare, Inc.
+Added: Insider Trading Policy, dated January 21, 2025.
+Added: Incorporated by reference to Exhibit 19.1 to the Company’s Annual Report on Form 10-K filed on March 10, 2025.
*21.1 Subsidiaries of the Registrant.
40 unchanged sentences
William Frazier
−Removed: /s/ Bruce Greenstein Director March 10, 2025
−Removed: Bruce Greenstein
/s/ Sabrina Heltz Director March 4, 2026
5 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.